Chemical Structure (Image 01)
Lisdexamfetamine Dimesylate Capsule
Product Images NDC 43547-607
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 43547-607). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Solco Healthcare Us,llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure1 (Image 02)
Figure 2 (Image 03)
Figure 3 (Image 04)
Interacting drug: Guanfacine, Venlafaxine
CYP1A2 Substrates: Caffeine
CYP2D6 Substrates: Dextromethorphan
CYP2C19 Substrates: Omeprazole
CYP3A Substrates: Midazolam
PK parameters: Cmax and AUC
Fold Change and 90% confidence interval (CI):
- The fold change for the interaction is 0.0
- T T T indicates no significant change relative to the reference
- The change relative to reference is 20%*
Figure 4 (Image 05)
The given text appears to be a table showing LS Mean (SE) SKAMP Deportment Scores for a study involving a placebo and lisdexamfetamine dimesylate capsules. The table includes scores at different time points post-dose. However, the specific information regarding the scores and their interpretation is not available.*
Figure5 (Image 06)
Figure 6 (Image 07)
Figure7 (Image 08)
Figure 8 (Image 09)
10 (Image 10)
20 (Image 11)
Each capsule contains 20 mg of Lisdexamfetamine dimesylate, which is equivalent to 11.6 mg of lisdexamfetamine. The recommended storage temperature is between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F to 86°F). The medication is defined in the USP. It is manufactured by Prinston Laboratories in Charlotte, NC and distributed by Solco Healthcare US LLC in Somerset, NJ. The package insert should be referred to for dosage information.*
40 (Image 12)
Each capsule contains 30 mg of Lisdexamfetamine dimesylate, which is equivalent to 17.3 mg of lisdexamfetamine. This medication should be stored at room temperature, between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F). It is important to consult the package insert for specific dosage information. The medication is defined in the USP and is distributed by Solco Healthcare US, LLC, based in Somerset, NJ, USA. The manufacturer of the medication is Prinston Laboratories located in Charlotte, NC, USA. Unfortunately, no additional information is available from the provided text.*
40 (Image 13)
50 (Image 14)
This text is a description of a medication called Lisdexamfetamine dimesylate. Each capsule contains 50 mg of the medication, which is equivalent to 28.9 mg of lisdexamfetamine. The recommended storage temperature is between 20°C and 25°C (68°F to 77°F). The medication is defined in the USP. Additional information, such as dosage instructions and distribution details, can be found in the package insert.*
60 (Image 15)
Not available.*
70 (Image 16)
This text is a package insert for a medication called Lisdexamfetamine dimesylate. Each capsule contains 70 mg of the active ingredient, which is equivalent to 40.5 mg of lisdexamfetamine. The recommended dosage information is provided in the package insert. The medication should be stored at room temperature, between 20°C and 25°C (68°F to 77°F), with permitted excursions between 15°C and 30°C (59°F and 86°F). The medication is manufactured by Prinston Laboratories in Charlotte, USA, and distributed by Solco Healthcare USLLC in Somerset, USA. The insert mentions a separate medication guide provided to each patient. Unfortunately, the remaining part of the text is not legible.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
